MedTrace Logo

Consumption of Oral Artificial Sweeteners on Platelet Aggregation and Polyol Excretion

NCT04731363 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-05-22

Study results available
· View outcomes & findings →

Summary

The principal goal for the study is to examine whether ingestion of a beverage containing artificial sweeteners alters in vitro platelet aggregation.

Because of the increasing number of cardiometabolic diseases, such as diabetes mellitus, in the population, the use of artificial sweeteners to replace free sugars has been gaining popularity. Two popular artificial sweeteners are erythritol and xylitol. Erythritol and xylitol are both naturally occurring polyols found in fruits and vegetables. They are potent artificial sweeteners with a higher sweetening intensity and lower calorie content than table sugar.

Previous research has shown that the higher levels of sugar alcohols, like those used as artificial sweeteners, in the blood are related to a higher risk of cardiovascular complications, like heart attacks and strokes, and death. This may be because higher levels of sugar alcohols in one's blood may increase the activity of platelets, which would then increase the risk of heart attack and stroke. The investigators therefore want to find if consuming a single beverage that contains an artificial sweetener can raise the levels of sugar alcohols in the blood and if it can alter platelet function or aggregation.

Conditions

  • Cardiovascular Risk Factor

Interventions

DIETARY_SUPPLEMENT

xylitol, 30g

Intervention is a drink consisting of 300mL of water containing 30g of xylitol as a single oral dose.

DIETARY_SUPPLEMENT

erythritol, 30g

Intervention is a drink consisting of 300mL of water containing 30g of erythritol as a single oral dose.

DIETARY_SUPPLEMENT

xylitol, 5g

Intervention is a drink consisting of 300mL of water containing 5g of xylitol as a single oral dose.

DIETARY_SUPPLEMENT

glucose, 30g

Intervention is a drink consisting of 300mL of water containing 30g of glucose (dextrose) as a single oral dose.

Sponsors & Collaborators

  • The Cleveland Clinic

    lead OTHER

Principal Investigators

  • Wilson Tang, MD · The Cleveland Clinic

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-10
Primary Completion
2023-08-30
Completion
2026-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04731363 on ClinicalTrials.gov